X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the manufacturing and clinical trials of potent inhibitor known as HM43239 (tuspetinib) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).
Lead Product(s): Tuspetinib,Venetoclax
Therapeutic Area: Oncology Product Name: HM43239
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Aptose Biosciences
Deal Size: $13.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 31, 2024
Details:
The proceeds will be used for Aptose’s lead hematology drug, tuspetinib, formerly HM43239, an orally active small molecule inhibitor of FLT3, currently in Phase 1/2 trial in which patients with R/R AML receive tuspetinib monotherapy or in combination with venetoclax.
Lead Product(s): Tuspetinib,Venetoclax
Therapeutic Area: Oncology Product Name: HM43239
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Aptose Biosciences
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 06, 2023
Details:
Rosuzet is a combination of rosuvastatin is an inhibitor of HMG CoA-reductase, the rate-limiting enzyme that converts the precursor of cholesterol and ezetimibe, a sterol transporter, NPC1L1, which is involved in the intestinal uptake of cholesterol.
Lead Product(s): Rosuvastatin,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Rosuzet
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2023
Details:
Under the terms of the agreement, Hanmi has granted Aptose exclusive worldwide rights to HM43239 for all indications. HM43239 is a well-tolerated, once-daily oral agent with validated anti-leukemic activity in a highly challenging and heterogeneous malignancy like AML.
Lead Product(s): Tuspetinib
Therapeutic Area: Oncology Product Name: HM43239
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aptose Biosciences
Deal Size: $420.0 million Upfront Cash: $12.5 million
Deal Type: Licensing Agreement November 09, 2021
Details:
Genexine 's GX-19N COVID-19 vaccine candidate is a DNA based vaccine and showed no severe side effects. Hanmi will begin producing 10M doses of Genexine’s experimental COVID-19 vaccine with an aim to gradually ramp up production capacity to millions of doses by 2022.
Lead Product(s): GX-19N
Therapeutic Area: Infections and Infectious Diseases Product Name: GX-19N
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Genexine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 18, 2021
Details:
Rolontis," a treatment for neutropenia and "Oraxol," as a treatment for metastatic breast cancer are under priority review by FDA. Hanmi is about to announce the results of their BLA/NDA approval respectively.
Lead Product(s): Eflapegrastim
Therapeutic Area: Oncology Product Name: Rolontis
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Spectrum Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2021
Details:
Under the agreement, Merck will be granted an exclusive license to develop, manufacture and commercialize efinopegdutidein the United States and globally.
Lead Product(s): Efinopegdutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: HM12525A
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $870.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement August 04, 2020
Details:
The novel drug is under development with the company’s Lapscovery, a platform technology that prolongs the duration of action of biologics, making it possible for patients to take weekly or monthly administration.
Lead Product(s): HM15211
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: HM15211
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2020
Details:
Hanmi is planning to begin the global Phase 2 trials of LAPSTriple Agonist in the second quarter this year with biopsy-proven NASH patients.
Lead Product(s): HM15211
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2020
Details:
HM12525A is the world's first anti-obesity treatment that works as a once-weekly injection. Its efficacy was proven to be higher than existing daily-injection obesity treatment in Phase 2 trials.
Lead Product(s): HM15211
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
